Internship

Co-op

Purification Process Development

Confirmed live in the last 24 hours

Sanofi

Sanofi

10,001+ employees

Develops pharmaceuticals and life-saving vaccines

Biotechnology
Healthcare

No H1B Sponsorship

Framingham, MA, USA

Must be able to relocate to Framingham, MA and work 40 hours/week, Monday-Friday.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • Currently pursuing a bachelor's or master's degree in biology, chemistry, chemical or biochemical engineering, biotech, or a related field at an accredited college or university with the expectation that you will complete your current degree by the Spring 2027
  • Must be enrolled in school the semester following your co-op with Sanofi.
  • Must be able to relocate to the office location and work 40hrs/week, Monday-Friday, for the full duration of the co-op
  • Must have permanent US work authorization
Responsibilities
  • The responsibilities of the Co-op will include conducting experiments using small scale chromatography columns and filtration units and/or high-throughput technologies to develop, characterize, and optimize new processes.
  • The student may also contribute to technology development projects focused on development of next-generation bioprocessing and process development technologies, such as integrated and continuous bioprocessing, high throughput process development, and mechanistic modeling of bioprocesses.
  • On-the-job training will be provided as necessary to teach the technical skills required to perform their duties.

Sanofi provides healthcare solutions through its pharmaceutical and biotechnology products, focusing on treatments and vaccines for various medical conditions. The company conducts extensive research and development to create new therapies and improve existing ones, particularly in areas like immunology, oncology, and rare diseases. Sanofi differentiates itself from competitors by its strong commitment to scientific innovation and a diverse product portfolio that includes prescription medicines and vaccines. Its goal is to enhance health outcomes and improve the quality of life for people globally by delivering effective and safe healthcare solutions.

Company Stage

IPO

Total Funding

$2B

Headquarters

Paris, France

Founded

1973

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Dupixent's EU approval for young children with EoE expands its market reach significantly.
  • Sanofi's investment in SureChill supports sustainable vaccine preservation in emerging markets.
  • Collaboration with Orano Med enhances Sanofi's position in innovative cancer treatments.

What critics are saying

  • Increased competition in multiple myeloma treatments may impact Sarclisa's market share.
  • Regulatory delays could hinder rilzabrutinib's market entry and revenue generation.
  • High costs of AI tools like Muse may not yield expected efficiency gains.

What makes Sanofi unique

  • Sanofi's Sarclisa shows significant benefits in multiple myeloma treatment, enhancing patient outcomes.
  • Rilzabrutinib is a pioneering BTK inhibitor for ITP, showing rapid and durable responses.
  • Sanofi's AI tool Muse accelerates patient recruitment, optimizing clinical trial efficiency.

Help us improve and share your feedback! Did you find this helpful?